Literature DB >> 23199480

Chemical and microbial semi-synthesis of tetrahydroprotoberberines as inhibitors on tissue factor procoagulant activity.

Hai-Xia Ge1, Jian Zhang, Ling Chen, Jun-Ping Kou, Bo-Yang Yu.   

Abstract

To discover new inhibitors on tissue factor procoagulant activity, 21 tetrahydroprotoberberines were screened on the model of human THP-1 cells stimulated by lipopolysaccharide. Among these tetrahydroprotoberberines, several unique compounds were synthesized through microbial transformation: compound 6 (l-corydalmine) was obtained through regio-selective demethylation by Streptomyces griseus ATCC 13273, whereas compounds 4a, 4b, 5h, and 5i were microbial glycosylation products by Gliocladium deliquescens NRRL1086. The bioassay results showed that compounds 3 (tetrahydroberberine), 10 (tetrahydroberberrubine), and 5f (cinnamyl ester of 5) and 5i (glycosidic product of 5), exhibited the most potential effects, with IC(50) values of 8.35, 6.75, 3.75, and 8.79 nM, respectively. The preliminary structure and activity relationship analysis revealed that the 2,3-methylenedioxy group of the A ring was essential for the strong inhibitory effects, and the R configuration of the chiral center C-14 showed higher activity than S-form products. The formation of fatty acid or aromatic acid esters of compound 5, except the cinnamyl esters, would weaken its effects. It is also interesting to note that the glycosylation of tetrahydroprotoberberines will maintain and even enhance the inhibitory effects. Because of the importance of glycochemistry in new drug discovery and development, this deserves further exploration and may provide some guide on the semi-synthesis of tetrahydroprotoberberines as tissue factor pathway inhibitors. Our findings also provide some potential leading compounds for tissue factor-related diseases, such as cancer and cardiovascular diseases.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23199480     DOI: 10.1016/j.bmc.2012.11.002

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  6 in total

1.  Significantly different effects of tetrahydroberberrubine enantiomers on dopamine D1/D2 receptors revealed by experimental study and integrated in silico simulation.

Authors:  Haixia Ge; Yuemin Bian; Xibing He; Xiang-Qun Xie; Junmei Wang
Journal:  J Comput Aided Mol Des       Date:  2019-03-06       Impact factor: 3.686

2.  Colloidal aggregation and the in vitro activity of traditional Chinese medicines.

Authors:  Da Duan; Allison K Doak; Lyudmila Nedyalkova; Brian K Shoichet
Journal:  ACS Chem Biol       Date:  2015-02-09       Impact factor: 5.100

3.  Design, synthesis and biological evaluation of novel Schiff base-bridged tetrahydroprotoberberine triazoles as a new type of potential antimicrobial agents.

Authors:  Jun-Rong Duan; Han-Bo Liu; Ponmani Jeyakkumar; Lavanya Gopala; Shuo Li; Rong-Xia Geng; Cheng-He Zhou
Journal:  Medchemcomm       Date:  2017-02-16       Impact factor: 3.597

4.  Synthesis of 9-O-arylated berberines via copper-catalyzed CAr-O coupling reactions.

Authors:  Qiaoqiao Teng; Xinhui Zhu; Qianqian Guo; Weihua Jiang; Jiang Liu; Qi Meng
Journal:  Beilstein J Org Chem       Date:  2019-07-15       Impact factor: 2.883

5.  Berberine Targets AP-2/hTERT, NF-κB/COX-2, HIF-1α/VEGF and Cytochrome-c/Caspase Signaling to Suppress Human Cancer Cell Growth.

Authors:  Lingyi Fu; Wangbing Chen; Wei Guo; Jingshu Wang; Yun Tian; Dingbo Shi; Xiaohong Zhang; Huijuan Qiu; Xiangsheng Xiao; Tiebang Kang; Wenlin Huang; Shusen Wang; Wuguo Deng
Journal:  PLoS One       Date:  2013-07-15       Impact factor: 3.240

6.  Design, synthesis, and biological evaluation of novel tetrahydroprotoberberine derivatives (THPBs) as proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators for the treatment of hyperlipidemia.

Authors:  Chenglin Wu; Cong Xi; Junhua Tong; Jing Zhao; Hualiang Jiang; Jiang Wang; Yiping Wang; Hong Liu
Journal:  Acta Pharm Sin B       Date:  2019-06-25       Impact factor: 11.413

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.